Asymmetric dimethylarginine, race, and mortality in hemodialysis patients.
+4 authors
Journal: 2015/April - Clinical Journal of the American Society of Nephrology
ISSN: 1555-905X
Abstract:
OBJECTIVE
Levels of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase, are elevated in kidney disease and associated with mortality in white European hemodialysis populations. Nitric oxide production and degradation are partially genetically determined and differ by racial background. No studies have measured asymmetric dimethylarginine in African Americans on dialysis and assessed whether differences exist in its association with mortality by race.
METHODS
Asymmetric dimethylarginine was measured in 259 patients on maintenance hemodialysis assembled from 2004 to 2012 in Boston area outpatient centers. Cox proportional hazards models were used to determine the association between asymmetric dimethylarginine and all-cause mortality, and an interaction with race was tested.
RESULTS
Mean (SD) age was 63 (17) years, 46% were women, and 22% were African American. Mean asymmetric dimethylarginine in non-African Americans was 0.79 µmol/L (0.16) versus 0.70 µmol/L (0.11) in African Americans (P<0.001); 130 patients died over a median follow-up of 2.3 years. African Americans had lower mortality risk than non-African Americans (hazard ratio, 0.27; 95% confidence interval, 0.15 to 0.50) that was robust to adjustment for age, comorbidity, and asymmetric dimethylarginine (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.69). An interaction was noted between race and asymmetric dimethylarginine (P=0.03), such that asymmetric dimethylarginine was associated with higher mortality in non-African Americans (adjusted hazard ratio, 1.29; 95% confidence interval, 1.06 to 1.57 per 1 SD higher asymmetric dimethylarginine) but not in African Americans (adjusted hazard ratio, 0.57; 95% confidence interval, 0.28 to 1.18). Additional adjustment for fibroblast growth factor 23 partially attenuated the association for non-African Americans (adjusted hazard ratio, 1.22; 95% confidence interval, 0.98 to 1.50).
CONCLUSIONS
African Americans have lower asymmetric dimethylarginine levels and lower hazard for mortality compared with non-African Americans. Levels of asymmetric dimethylarginine did not explain lower hazard for mortality in non-African American patients. High asymmetric dimethylarginine was a risk factor for mortality exclusively in non-African Americans. Mechanisms explaining these relationships need to be evaluated.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(5)
References
(35)
Diseases
(1)
Drugs
(1)
Chemicals
(1)
Organisms
(1)
Processes
(1)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Clin J Am Soc Nephrol 9(8): 1426-1433
PMID: 24970872

Asymmetric Dimethylarginine, Race, and Mortality in Hemodialysis Patients

Background and objectives

Levels of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase, are elevated in kidney disease and associated with mortality in white European hemodialysis populations. Nitric oxide production and degradation are partially genetically determined and differ by racial background. No studies have measured asymmetric dimethylarginine in African Americans on dialysis and assessed whether differences exist in its association with mortality by race.

Design, setting, participants, &amp; measurements

Asymmetric dimethylarginine was measured in 259 patients on maintenance hemodialysis assembled from 2004 to 2012 in Boston area outpatient centers. Cox proportional hazards models were used to determine the association between asymmetric dimethylarginine and all-cause mortality, and an interaction with race was tested.

Results

Mean (SD) age was 63 (17) years, 46% were women, and 22% were African American. Mean asymmetric dimethylarginine in non–African Americans was 0.79 µmol/L (0.16) versus 0.70 µmol/L (0.11) in African Americans (P<0.001); 130 patients died over a median follow-up of 2.3 years. African Americans had lower mortality risk than non–African Americans (hazard ratio, 0.27; 95% confidence interval, 0.15 to 0.50) that was robust to adjustment for age, comorbidity, and asymmetric dimethylarginine (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.69). An interaction was noted between race and asymmetric dimethylarginine (P=0.03), such that asymmetric dimethylarginine was associated with higher mortality in non–African Americans (adjusted hazard ratio, 1.29; 95% confidence interval, 1.06 to 1.57 per 1 SD higher asymmetric dimethylarginine) but not in African Americans (adjusted hazard ratio, 0.57; 95% confidence interval, 0.28 to 1.18). Additional adjustment for fibroblast growth factor 23 partially attenuated the association for non–African Americans (adjusted hazard ratio, 1.22; 95% confidence interval, 0.98 to 1.50).

Conclusions

African Americans have lower asymmetric dimethylarginine levels and lower hazard for mortality compared with non–African Americans. Levels of asymmetric dimethylarginine did not explain lower hazard for mortality in non–African American patients. High asymmetric dimethylarginine was a risk factor for mortality exclusively in non–African Americans. Mechanisms explaining these relationships need to be evaluated.

Supplementary Material

Supplemental Data:
Division of Nephrology, Department of Medicine,
Institute for Clinical Research and Health Policy Studies, and
Department of Psychiatry, Tufts Medical Center, Boston, Massachusetts;
Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; and
Department of Laboratory Medicine, University Hospital of Padua, Padua, Italy
Corresponding author.
Correspondence: Dr. Mark J. Sarnak, Box 391, Division of Nephrology, Tufts Medical Center, 800 Washington Street, Boston, MA 02111. Email: gro.retneclacidemstfut@kanrasm
Received 2014 Jan 21; Accepted 2014 May 12.
Copyright © 2014 by the American Society of Nephrology

Abstract

Background and objectives

Levels of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase, are elevated in kidney disease and associated with mortality in white European hemodialysis populations. Nitric oxide production and degradation are partially genetically determined and differ by racial background. No studies have measured asymmetric dimethylarginine in African Americans on dialysis and assessed whether differences exist in its association with mortality by race.

Design, setting, participants, &amp; measurements

Asymmetric dimethylarginine was measured in 259 patients on maintenance hemodialysis assembled from 2004 to 2012 in Boston area outpatient centers. Cox proportional hazards models were used to determine the association between asymmetric dimethylarginine and all-cause mortality, and an interaction with race was tested.

Results

Mean (SD) age was 63 (17) years, 46% were women, and 22% were African American. Mean asymmetric dimethylarginine in non–African Americans was 0.79 µmol/L (0.16) versus 0.70 µmol/L (0.11) in African Americans (P<0.001); 130 patients died over a median follow-up of 2.3 years. African Americans had lower mortality risk than non–African Americans (hazard ratio, 0.27; 95% confidence interval, 0.15 to 0.50) that was robust to adjustment for age, comorbidity, and asymmetric dimethylarginine (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.69). An interaction was noted between race and asymmetric dimethylarginine (P=0.03), such that asymmetric dimethylarginine was associated with higher mortality in non–African Americans (adjusted hazard ratio, 1.29; 95% confidence interval, 1.06 to 1.57 per 1 SD higher asymmetric dimethylarginine) but not in African Americans (adjusted hazard ratio, 0.57; 95% confidence interval, 0.28 to 1.18). Additional adjustment for fibroblast growth factor 23 partially attenuated the association for non–African Americans (adjusted hazard ratio, 1.22; 95% confidence interval, 0.98 to 1.50).

Conclusions

African Americans have lower asymmetric dimethylarginine levels and lower hazard for mortality compared with non–African Americans. Levels of asymmetric dimethylarginine did not explain lower hazard for mortality in non–African American patients. High asymmetric dimethylarginine was a risk factor for mortality exclusively in non–African Americans. Mechanisms explaining these relationships need to be evaluated.

Keywords: mortality risk, hemodialysis, nitric oxide
Abstract

Presented as mean±SD, median (interquartile range), or percentage. Q, quartile; ADMA, asymmetric dimethylarginine; HF, heart failure; CVD, cardiovascular disease (composite of history of peripheral vascular disease or coronary artery disease); CRP, high-sensitivity C-reactive protein; FGF-23, fibroblast growth factor 23; RU, relative units.

CVD, cardiovascular disease (composite of history of peripheral vascular disease or coronary artery disease); 95% CI, 95% confidence interval.

HR per 1 SD change in asymmetric dimethylarginine (0.15 µmol/L), except for quartile analysis. HR, hazard ratio.

Click here to view.

Acknowledgments

We acknowledge the assistance of Dialysis Clinic, Inc. (DCI) and, in particular, the staff and patients at the five DCI units in the Boston area and St. Elizabeth’s Dialysis Unit, whose generous cooperation made this study possible. This work was prepared as part of the master’s thesis of D.A.D at the Tufts Clinical and Translational Science Institute (CTSI), and therefore, we thank the Tufts CTSI for guidance in completing this work.

The study was funded by an American Society of Nephrology Research Fellowship Grant (to D.A.D.) and National Institutes of Health Grants K23-DK71636 (to D.E.W.), R21-DK068310 (to M.J.S.), and R01-DK078204 (to M.J.S.).

Acknowledgments

Footnotes

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.00770114/-/DCSupplemental.

Footnotes

References

  • 1. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet339: 572–575, 1992 [[PubMed]
  • 2. Anderstam B, Katzarski K, Bergström J: Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients.J Am Soc Nephrol8: 1437–1442, 1997 [[PubMed]
  • 3. Cooke JP, Ghebremariam YT: Dietary nitrate, nitric oxide, and restenosis.J Clin Invest121: 1258–1260, 2011
  • 4. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study.Lancet358: 2113–2117, 2001 [[PubMed]
  • 5. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach.J Am Soc Nephrol16: 2449–2455, 2005 [[PubMed]
  • 6. Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.Clin J Am Soc Nephrol4: 1115–1120, 2009
  • 7. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, Montgomery RA, Segev DL: Association of race and age with survival among patients undergoing dialysis.JAMA306: 620–626, 2011
  • 8. Robinson BM, Joffe MM, Pisoni RL, Port FK, Feldman HI: Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study.J Am Soc Nephrol17: 2910–2918, 2006 [[PubMed]
  • 9. Bloembergen WE, Port FK, Mauger EA, Wolfe RA: Causes of death in dialysis patients: Racial and gender differences.J Am Soc Nephrol5: 1231–1242, 1994 [[PubMed]
  • 10. Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, Cheung AK: The relationship of age, race, and ethnicity with survival in dialysis patients.Clin J Am Soc Nephrol8: 953–961, 2013
  • 11. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL, Cohn JN, Worcel M: Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: Results from the A-HeFT trial.J Card Fail15: 191–198, 2009 [[PubMed]
  • 12. Fogarty RD, Abhary S, Javadiyan S, Kasmeridis N, Petrovsky N, Whiting MJ, Craig JE, Burdon KP: Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes.J Diabetes Complications26: 195–198, 2012 [[PubMed]
  • 13. Pope AJ, Karuppiah K, Cardounel AJ: Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.Pharmacol Res60: 461–465, 2009
  • 14. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, African American Heart Failure Trial Investigators : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.N Engl J Med351: 2049–2057, 2004 [[PubMed]
  • 15. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN, African American Heart Failure Trial Investigators : Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: Consistency across subgroups in the African American Heart Failure Trial.Circulation115: 1747–1753, 2007 [[PubMed]
  • 16. Sarnak MJ, Tighiouart H, Scott TM, Lou KV, Sorensen EP, Giang LM, Drew DA, Shaffi K, Strom JA, Singh AK, Weiner DE: Frequency of and risk factors for poor cognitive performance in hemodialysis patients.Neurology80: 471–480, 2013
  • 17. Ivanova M, Artusi C, Boffa GM, Zaninotto M, Plebani M: HPLC determination of plasma dimethylarginines: Method validation and preliminary clinical application.Clin Chim Acta411: 1632–1636, 2010 [[PubMed]
  • 18. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R, CREED Investigators : Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.Kidney Int62: 339–345, 2002 [[PubMed]
  • 19. Bode-Böger SM, Scalera F, Ignarro LJ: The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio.Pharmacol Ther114: 295–306, 2007 [[PubMed]
  • 20. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in humans.Stroke37: 2024–2029, 2006 [[PubMed]
  • 21. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Böger R, CREED Investigators : Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.J Am Soc Nephrol13: 490–496, 2002 [[PubMed]
  • 22. Tutarel O, Denecke A, Bode-Böger SM, Martens-Lobenhoffer J, Lovric S, Bauersachs J, Schieffer B, Westhoff-Bleck M, Kielstein JT: Asymmetrical dimethylarginine—more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease.PLoS ONE7: e33795, 2012
  • 23. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.Kidney Int78: 679–685, 2010 [[PubMed]
  • 24. Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, Duncan ER, Shah AM, Kearney MT: Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men.Hypertension49: 873–877, 2007 [[PubMed]
  • 25. Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS, ADVANCE Investigators : Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities.Clin Chem56: 111–120, 2010 [[PubMed]
  • 26. Böger RH, Zoccali C: ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.Atheroscler Suppl4: 23–28, 2003 [[PubMed]
  • 27. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A: Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.Am J Kidney Dis48: 797–805, 2006 [[PubMed]
  • 28. Kovesdy CP, Quarles LD, Lott EH, Lu JL, Ma JZ, Molnar MZ, Kalantar-Zadeh K: Survival advantage in black versus white men with CKD: Effect of estimated GFR and case mix.Am J Kidney Dis62: 228–235, 2013
  • 29. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS: Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.Circulation119: 1592–1600, 2009
  • 30. Anderssohn M, Rosenberg M, Schwedhelm E, Zugck C, Lutz M, Lüneburg N, Frey N, Böger RH: The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy.J Card Fail18: 904–911, 2012 [[PubMed]
  • 31. Li R, Lyn D, Lapu-Bula R, Oduwole A, Igho-Pemu P, Lankford B, Morgan J, Nkemdechi S, Liu G, Pack C, Silvestrov N, von Deutsch DA, Song Q, Abukhalaf IK, Ofili E: Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans.Am J Hypertens17: 560–567, 2004 [[PubMed]
  • 32. Tanus-Santos JE, Desai M, Flockhart DA: Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants.Pharmacogenetics11: 719–725, 2001 [[PubMed]
  • 33. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.Arterioscler Thromb Vasc Biol23: 1455–1459, 2003 [[PubMed]
  • 34. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P: Disruption of methylarginine metabolism impairs vascular homeostasis.Nat Med13: 198–203, 2007 [[PubMed]
  • 35. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske BL, Kutner N, Liu J, St Peter W, Guo H, Hu Y, Kats A, Li S, Li S, Maloney J, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Weinhandl E, Xiong H, Yusuf A, Zaun D, Arko C, Chen S-C, Daniels F, Ebben J, Frazier E, Johnson R, Sheets D, Wang X, Forrest B, Berrini D, Constantini E, Everson S, Eggers P, Agodoa L: US Renal Data System 2013 Annual Data Report.Am J Kidney Dis63Suppl]: A7, 2014 [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.